deamidation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-12 and is reviewed periodically as new material appears.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Stability studies focus on deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation into higher-order species. The fatty acid side chain adds susceptibility to oxidative change and can promote self-association at high concentration. Lyophilised material is comparatively robust when kept cold and dry, while aqueous solutions require refrigeration and protection from light. Forced degradation experiments under heat, acid, base, and peroxide conditions establish the specificity of each analytical method. Which degradation route dominates under real storage conditions depends on the formulation and stays formulation-specific.
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
A very important modification of eukaryotic pre-mRNA is RNA splicing. The majority of eukaryotic pre-mRNAs consist of alternating segments called exons and introns. During the process of splicing, an RNA-protein catalytical complex known as spliceosome catalyzes two transesterification reactions, which remove an intron and release it in form of lariat structure, and then splice neighbouring exons together. In certain cases, some introns or exons can be either removed or retained in mature mRNA. This so-called alternative splicing creates series of different transcripts originating from a single gene. Because these transcripts can be potentially translated into different proteins, splicing extends the complexity of eukaryotic gene expression and the size of a species proteome. Extensive RNA processing may be an evolutionary advantage made possible by the nucleus of eukaryotes. In prokaryotes, transcription and translation happen together, whilst in eukaryotes, the nuclear membrane separates the two processes, giving time for RNA processing to occur.
=== Social definition === Cultural variation can define hyperandrogenism socially—apart from clinical and chemical definitions—to make some hair growth unacceptable even if it is considered clinically normal based on metrics like the Ferriman-Gallwey score. For example, only pubic and axillary hair may be tolerated in North American women, while other androgen-dependent hair such as growth on the upper lip, over the linea alba, on the thighs, and around the areola is not.
== Sources == Joan E. Howard, From Violence to Vision: Sacrifice in the Works of Marguerite Yourcenar (1992) Josyane Savigneau, Marguerite Yourcenar: Inventing a Life (1993). George Rousseau, Marguerite Yourcenar: A Biography (London: Haus Publishing, 2004). Judith Holland Sarnecki, Subversive Subjects: Reading Marguerite Yourcenar (2004) Giorgetto Giorgi, "Il Grand Tour e la scoperta dell’antico nel Labyrinthe du monde di Marguerite Yourcenar," in Sergio Audano, Giovanni Cipriani (ed.), Aspetti della Fortuna dell'Antico nella Cultura Europea: atti della settima giornata di studi, Sestri Levante, 19 March 2010 (Foggia: Edizioni il Castello, 2011) (Echo, 1), 99–108. Les yeux ouverts, entretiens avec Mathieu Galey (Éditions du Centurion « Les interviews », 1980). Bérengère Deprez, Marguerite Yourcenar et les États-Unis. Du nageur à la vague, Éditions Racine, 2012, 192 p. Bérengère Deprez, Marguerite Yourcenar and the United States. From Prophecy to Protest, Peter Lang, coll. « Yourcenar », 2009, 180 p. Deprez, Marguerite Yourcenar. Écriture, maternité, démiurgie, essai, Bruxelles, Archives et musée de la littérature/PIE-Peter Lang, coll. « Documents pour l’histoire des francophonies », 2003, 330 p. Donata Spadaro, Marguerite Yourcenar et l'écriture autobiographique : Le Labyrinthe du monde, bull. SIEY, no 17, décembre 1996, p. 69 à 83 Donata Spadaro, Marguerite Yourcenar e l'autobiografia (ADP, 2014) Mireille Brémond, Marguerite Yourcenar, une femme à l'Académie (Garnier, 2019);. Rémy Poignault, L'Antiquité dans l'œuvre de Marguerite Yourcenar.
==== Glutathione ==== Glutathione or its homologues, e.g. homoglutathione in Fabaceae; hydroxymethylglutathione in Poaceae are the major water-soluble non-protein thiol compounds present in plant tissue and account for 1-2% of the total sulfur. The content of glutathione in plant tissue ranges from 0.1 – 3 mM. Cysteine is the precursor to glutathione (and its homologues). First, γ-glutamylcysteine is synthesized from cysteine and glutamate catalyzed by gamma-glutamylcysteine synthetase. Second, glutathione is synthesized from γ-glutamylcysteine and glycine (in glutathione homologues, β-alanine or serine) catalyzed by glutathione synthetase. Both steps of the synthesis of glutathione are ATP-dependent. Glutathione is maintained in the reduced form by an NADPH-dependent glutathione reductase, and the ratio of reduced glutathione (GSH) to oxidized glutathione (GSSG) generally exceeds a value of 7. In sulfur metabolism glutathione is reductant for the conversion of APS to sulfite. It is also the major transport form of reduced sulfur in plants. Roots likely largely depend for their reduced sulfur supply on shoot/root transfer of glutathione via the phloem, since the reduction of sulfur occurs predominantly in the chloroplast. Glutathione is also involved in the reduction and assimilation of selenite into selenocysteine.
Sources: en.wikipedia.org
== Biosynthesis == The biosynthesis of tyrocidine is similar to that of gramicidin S, and is achieved through the use of nonribosomal protein synthetases (NRPSs). Its biosynthesis is via an enzymatic assembly consisting of 3 peptide synthetase proteins, TycA, TycB, and TycC, which contain 10 modules. The different tyrocidine analogues (A–D) are not produced by different enzymes, but rather by an enzyme system that is capable of incorporating different amino acids of structural similarity at specified sites. The amino acid sequence is determined by the organization of the enzyme and not by any RNA template.
Suvomipic (INNTooltip International Nonproprietary Name; developmental code names PP405 and JXL069) is a drug acting as a mitochondrial pyruvate carrier (MPC) inhibitor which is under development for the treatment of alopecia (hair loss), specifically androgenic alopecia (pattern hair loss). It is used topically as a 0.05% concentration gel on the scalp once-daily. Suvomipic is a possible first-in-class drug with a novel mechanism of action in the potential treatment of hair loss. The drug's generic name and chemical structure were published in July 2026, revealing PP405 to be the existing compound JXL069.
=== Family history === A family history of end-stage renal disease with hearing impairment is suggestive of Alport syndrome, but other conditions can cause this combination of abnormalities. Most can be distinguished by clinical features. The finding of haematuria in relatives is suggestive. While X-linked inheritance is the most common pattern, genetic testing is revealing that atypical presentations may be more common than currently thought.
Sources: en.wikipedia.org
The primary purpose of freeze drying within the food industry is to extend the shelf-life of the food while maintaining the quality. Freeze-drying is known to result in the highest quality of solid foods of all drying techniques because structural integrity is maintained along with preservation of flavors. Because freeze drying is expensive, it is used mainly with high-value products. Examples of high-value freeze-dried products are seasonal fruits and vegetables because of their limited availability, and foods used for military rations, astronauts/cosmonauts, and/or hikers. Water-based drinks such as coffee and tea are also freeze-dried. Compared to heat-based drying, freeze-drying preserves more volatile aroma compounds. Freeze-drying is also used to make instant soup bricks. It can also preserve raw ingredients such as egg whites for baking.
=== Legal status === In May 2022, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Upstaza, intended for the treatment of aromatic L‑amino acid decarboxylase (AADC) deficiency. As Upstaza is an advanced therapy medicinal product, the CHMP positive opinion is based on an assessment by the Committee for Advanced Therapies. The applicant for this medicinal product is PTC Therapeutics International Limited. Eladocagene exuparvovec was approved for medical use in the European Union in July 2022. Eladocagene exuparvovec was approved for medical use in the United States in November 2024. The US Food and Drug Administration (FDA) granted the application for eladocagene exuparvovec priority review and orphan drug designations, and a rare pediatric disease priority review voucher. It was approved under the accelerated approval pathway. The FDA granted approval of Kebilidi to PTC Therapeutics.
== Advantages == SMB provides lower production cost by requiring less column volume, less chromatographic separation media ("packing" or "stationary phase"), using less solvent and less energy, and requiring far less labor. At industrial scale an SMB chromatographic separator is operated continuously, requiring less resin and less solvent than batch chromatography. The continuous operation facilitates operation control and integration into production plants.
Camouflage does not always fool a predator. When caught out, snake species adopt different defensive tactics and use a complicated set of behaviors when attacked. Some species, like cobras or hognose snakes, first elevate their head and spread out the skin of their neck in an effort to look large and threatening. Failure of this strategy may lead to other measures practiced particularly by cobras, vipers, and closely related species, which use venom to attack. The venom is modified saliva, delivered through fangs from a venom gland. Some non-venomous snakes, such as American hognose snakes or European grass snake, play dead when in danger; some, including the grass snake, exude a foul-smelling liquid to deter attackers.
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
Purity is commonly expressed as the percentage of the main peak relative to all integrated peaks in a reversed-phase chromatogram. Related substances and counter-ions are reported separately. Values obtained with different detectors are not always directly comparable.